Indaptus Therapeutics, Inc. 8-K

What Happened

• Indaptus Therapeutics, Inc. filed an 8-K on January 20, 2026 (Item 5.02) announcing that it modified employment agreements for two executive officers: Jeffrey A. Meckler (Co‑Chief Executive Officer) and Michael J. Newman, Ph.D. (Chief Science Officer). Effective January 15, 2026, each executive’s salary was set at $60,000 per year for the remainder of 2026. The salary adjustment agreements are attached as Exhibits 10.1 and 10.2.
• The filing also reports that director Anthony Maddaluna, who had earlier notified the company of his intention to resign effective at the next special meeting of stockholders, informed the company on January 20, 2026 that he is rescinding his resignation and will remain on the Board and continue serving on the Compensation and Nominating Committees.

Key Details

• Salary change effective: January 15, 2026.
• New salary for each executive: $60,000 per annum (for the remainder of 2026), subject to standard payroll deductions.
• Executives affected: Jeffrey A. Meckler (Co‑CEO) and Michael J. Newman, Ph.D. (CSO).
• Director update: Anthony Maddaluna will remain a Board member and continue on Compensation and Nominating Committees.

Why It Matters

• For investors, the salary reductions are a concrete cost-saving and liquidity measure that directly lower near-term cash burn from executive compensation. The change is documented as a compensatory arrangement (Exhibits 10.1 and 10.2).
• Retention of Mr. Maddaluna maintains Board continuity and committee composition, reducing potential short-term governance uncertainty ahead of the company’s special stockholder meeting.